Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs

Eli Lilly and Co (NYSE:LLY) on Wednesday shared topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials of oral orforglipron for reducing blood sugar levels.

ACHIEVE-2, the second head-to-head trial, evaluated orforglipron versus AstraZeneca Plc’s (NASDAQ:AZN) Farxiga (dapagliflozin) in adults with type 2 diabetes inadequately controlled on commonly used metformin.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.